SCHEMBL31172694

SCHEMBL31172694

O=C(Oc1c(F)c(F)c(F)c(F)c1F)c1ccc(Cn2cccn2)c(OC(F)(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KLKB1 P03952 2/20 0.38
▸ HTT P42858 2/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ DDR1 Q08345 5/20 0.36
▸ LMNA P02545 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ KAT7 O95251 3/20 0.35
▸ KAT6A Q92794 3/20 0.35
▸ KAT6B Q8WYB5 2/20 0.35
▸ ADRB2 P07550 1/20 0.35
▸ ADRB1 P08588 1/20 0.35
▸ ADRB3 P13945 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ KAT5 Q92993 1/20 0.35
▸ KAT8 Q9H7Z6 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172672 0.88 KAT7 (0.42) KLKB1HTTHDAC1HDAC6LMNA
SCHEMBL31172618 0.88 HDAC1 (0.42) KLKB1HTTHDAC1HDAC6DDR1
SCHEMBL31172644 0.85 KAT7 (0.42) KLKB1HTTHDAC1HDAC6LMNA
SCHEMBL31172670 0.85 HTT (0.53) KLKB1HTTHDAC1HDAC6ADRB2
SCHEMBL31172689 0.77 KDM4E (0.39) KLKB1HTTHDAC1HDAC6LMNA
SCHEMBL31516596 0.77 KAT7 (0.48) KLKB1KAT7KAT6AKAT6BKAT5
SCHEMBL553315 0.75 KLKB1 (0.47) KLKB1HTTHDAC1HDAC6LMNA
SCHEMBL31172593 0.75 EPHX2 (0.41) HTTHDAC1HDAC6KAT7KAT6A
SCHEMBL17221669 0.73 KLKB1 (0.50) KLKB1HTTHDAC1HDAC6LMNA
SCHEMBL31172565 0.73 KAT7 (0.40) KLKB1HTTHDAC1HDAC6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KLKB1 1815/4885HTT 508/4885HDAC1 9/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B KLKB1 1815/4885HTT 508/4885HDAC1 9/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KLKB1 4177/4885HTT 1323/4885HDAC1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback